Market Overview:
The global cervical cancer therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cervical cancer, rising awareness about cervical cancer and its prevention, and the launch of novel therapies. Based on type, the global cervical cancer therapeutics market is segmented into drugs and vaccines. The drugs segment is further sub-segmented into chemotherapeutic agents and targeted therapy agents. The vaccines segment is further sub-segmented into prophylactic vaccines and therapeutic vaccines. Based on application, the global cervical cancer therapeutics market is divided into hospital pharmacy and drug store segments. Regionally, North America dominates the global cervix cancer therapeutics market followed by Europe due to early adoption of novel therapies in these regions coupled with increasing incidence rates for cervix cancers in these regions respectively .
Product Definition:
Cervical Cancer Therapeutics are treatments used to cure cervical cancer. These treatments may include surgery, radiation therapy, and chemotherapy. The importance of cervical cancer therapeutics is that they can cure a potentially deadly disease.
Drug:
Drug is any substance or combination of substances that modifies or changes the way a body function or reacts to disease. It may also be used for the diagnosis, prevention, treatment, and cure of diseases. Drug can be natural (derived from plants and animals) as well as synthetic (man-made). Some drugs are legal; some are not. All drugs have side effects; some have serious side effects which can cause death while others having less serious ones that affect only the health.
Vaccine:
A vaccine is a preparation of virus or bacteria which is used to stimulate the body's immune system to fight against cancer. The most common types of vaccines are for measles, polio, chickenpox, and hepatitis B.
Vaccines have been proven to be an effective treatment for many diseases including cervical cancer.
Application Insights:
Based on application, the global market is segmented into hospital pharmacy, drug store and others. The hospital pharmacy segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as high usage rates of antineoplastic drugs and increasing awareness about these drugs among healthcare professionals. Moreover, an increase in cancer cases has resulted in a rise in demand for antineoplastic medicines which further drives growth.
The drug store segment is expected to grow at a lucrative rate over the forecast period due to rising use of anti-cancer drugs by individuals diagnosed with cervical cancer at an early stage when treatment is still possible through surgery or other alternative methods such as radiation therapy or chemotherapy that are less effective than modern medicine used for treating this disease (1). Drug stores offer low cost generic medicines thereby contributing towards revenue generation for this industry owing to their ability to provide efficient treatment without spending too much money (2).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to high incidence rate, presence of key players, and favorable reimbursement scenario. In addition, increasing government initiatives for vaccination programs is expected to fuel the growth during the forecast period. For instance, in 2015-2016 academic year FDA approved two new vaccines against HPV-6 and -11 (Gardasil) and HPV-16 (Gardase). These vaccines are indicated for prevention of cervical cancer in women aged 13 to 26 years old.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to rising awareness about early diagnosis coupled with growing disposable income especially among middle class population groups in countries such as China & India which have a high prevalence rate of this disease.
Key Companies: Pfizer Inc.; Merck & Co.
Growth Factors:
- Increasing incidence of cervical cancer: The global incidence of cervical cancer is increasing at a significant rate. This is mainly due to the rising prevalence of HPV infection, which is the primary cause of cervical cancer. According to a study by the World Health Organization (WHO), there were an estimated 528,000 new cases and 266,000 deaths from cervical cancer in 2012. These numbers are expected to rise in the coming years owing to population growth and aging.
- Growing awareness about cervical cancer: There is growing awareness among women about the risk factors and symptoms associated with cervical cancer. This has led to an increase in demand for early diagnosis and treatment options for the disease. In addition, governments and non-profit organizations are working towards spreading awareness about preventive measures against HPV infection and its potential consequences such as cervical cancer development.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cervical Cancer Therapeutics Market Research Report
By Type
Drug, Vaccine
By Application
Hospital Pharmacy, Drug Store
By Companies
Amgen, Biocon, Cipla, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline Plc, Merck & Co. Inc.,, Novartis AG, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Cervical Cancer Therapeutics Market Report Segments:
The global Cervical Cancer Therapeutics market is segmented on the basis of:
Types
Drug, Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Drug Store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Biocon
- Cipla
- Dr. Reddy's Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- Fresenius SE & Co. KGaA
- GlaxoSmithKline Plc
- Merck & Co. Inc.,
- Novartis AG
- Pfizer
Highlights of The Cervical Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drug
- Vaccine
- By Application:
- Hospital Pharmacy
- Drug Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cervical Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cervical cancer therapies are treatments used to treat cervical cancer. These treatments can include surgery, chemotherapy, and radiation therapy.
Some of the major companies in the cervical cancer therapeutics market are Amgen, Biocon, Cipla, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline Plc, Merck & Co. Inc.,, Novartis AG, Pfizer.
The cervical cancer therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cervical Cancer Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cervical Cancer Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cervical Cancer Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cervical Cancer Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cervical Cancer Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Cervical Cancer Therapeutics Market Size and Y-o-Y Growth
4.5.2 Cervical Cancer Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Cervical Cancer Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cervical Cancer Therapeutics Market Size Forecast by Type
5.2.1 Drug
5.2.2 Vaccine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cervical Cancer Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cervical Cancer Therapeutics Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Drug Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cervical Cancer Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cervical Cancer Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cervical Cancer Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Cervical Cancer Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cervical Cancer Therapeutics Market Size Forecast by Type
9.6.1 Drug
9.6.2 Vaccine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cervical Cancer Therapeutics Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Drug Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cervical Cancer Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Cervical Cancer Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cervical Cancer Therapeutics Market Size Forecast by Type
10.6.1 Drug
10.6.2 Vaccine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cervical Cancer Therapeutics Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Drug Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cervical Cancer Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cervical Cancer Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cervical Cancer Therapeutics Market Size Forecast by Type
11.6.1 Drug
11.6.2 Vaccine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cervical Cancer Therapeutics Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Drug Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cervical Cancer Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Cervical Cancer Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cervical Cancer Therapeutics Market Size Forecast by Type
12.6.1 Drug
12.6.2 Vaccine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cervical Cancer Therapeutics Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Drug Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cervical Cancer Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cervical Cancer Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cervical Cancer Therapeutics Market Size Forecast by Type
13.6.1 Drug
13.6.2 Vaccine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cervical Cancer Therapeutics Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Drug Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cervical Cancer Therapeutics Market: Competitive Dashboard
14.2 Global Cervical Cancer Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Biocon
14.3.3 Cipla
14.3.4 Dr. Reddy's Laboratories Ltd.
14.3.5 F. Hoffmann-La Roche Ltd.
14.3.6 Fresenius SE & Co. KGaA
14.3.7 GlaxoSmithKline Plc
14.3.8 Merck & Co. Inc.,
14.3.9 Novartis AG
14.3.10 Pfizer
